An Bioequivalence Study to Compare Two 2 mg/ml Liposomal Amphotericin B Injections in Healthy Subjects

Taiwan Liposome Company (TLC)

Status and phase

Completed

Phase 1

Conditions

Normal Healthy Subjects

Treatments

Drug: AmBisome

Drug: Liposomal Amphotericin B

Study type

Interventional

Funder types

Industry

Identifiers

NCT01652859

TLC166.2

Details and patient eligibility

About

The 2 × 2 crossover designed study is to evaluate the bioequivalence of two different liposomal amphotericin B injections after single IV infusion at the same dose in normal healthy subjects.

Enrollment

36 patients

Sex

All

Ages

20 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Subjects must be adults (> 20 years old) in good health on the basis of medical history, physical examination, electrocardiogram, chest X-ray, and routine laboratory evaluations.
Vital signs (after 3 minutes resting in a upright position) which are within the following ranges: Ear body temperature between 35.0-37.5 °C. Systolic blood pressure, 90-140 mm Hg. Diastolic blood pressure, 50-90 mm Hg. Pulse rate, 50-90 bpm
Fasting blood glucose < 100 mg/dL.
Body weight must be above 50 kg for men and 45 kg for women and within 20% of ideal body weight.
Negative urine drug screen at clinic check-in before each dosing
Able to sign informed consent prior to study.
Able to communicate well with the investigator and comply with the requirements of the study.
Pregnancy tests (female only): negative reaction

Exclusion criteria

Use of any prescription or over the counter medication within 14 days prior to investigational products administration; with the exception of acetaminophen (not more than 2 g/day) or vitamins.
A plan to take concomitant medications while enrolled in the study, with the exception of acetaminophen (not more than 2 g/day) or vitamins.
Presence of any acute or chronic medical condition within 2 weeks prior to investigational products administration, including but not limited to: hepatic, gastrointestinal, renal, hematologic (including coagulation), pulmonary, neurologic, respiratory, endocrine, or cardiovascular system abnormalities; psychiatrical disease including major psychiatric disorders (e.g., schizophrenia, bipolar disorder); acute infection; or other conditions that would interfere with the absorption, distribution, metabolism, or excretion of drugs. Evidence of impaired renal function as indicated by clinically significant abnormal creatinine or BUN values or abnormal urinary constituents (e.g., albuminuria) as judged by the investigator. Evidence of liver disease, hepatitis B, hepatitis C or liver injury as indicated by an clinically significant abnormal liver function profile such as GOT, GPT, g-GT, alkaline phosphatase, serum bilirubin, HBs Ag, or HCV Ab as judged by the investigator.
Hemoglobin less than 12 g/dL
Participation in any clinical investigation within 2 months or 5 half-lives, whichever is longer, prior to investigational products administration.
Donation or loss of more than 500 mL blood within 3 months prior to investigational products administration.
Subject is known for HIV infected.
Known allergy or hypersensitivity to amphotericin B or its analogs.
History of drug or alcohol abuse within 12 months prior to investigational products administration ; current consumption of alcohol in excess of 28 units/week (one unit is 6 oz of beer, ½ oz of hard liquor, or 2 oz of wine)
Subjects who, in the opinion of the investigator, should not participate in the study or may not be capable of following the study schedule for any reason.
Consumption of more than 36 to 40 oz (1.1-1.2 L) of caffeine-containing beverages per day
Consumption of any products containing grapefruit in the 3 days before clinic check-in.